[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100559712":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":30,"responsibleParty":62,"collaborators":64,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":10,"eligibilityCriteria":72,"healthyVolunteers":69,"sex":73,"minAge":74,"maxAge":10,"enrollmentInfo":75,"targetDuration":10,"studyType":78,"phases":10,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Wake Forest University Health Sciences","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-small cell lung cancer (NSCLC)",null,"Non-small cell lung cancer (NSCLC) patients treated with with immune checkpoint inhibitor.",[13],"Behavioral: Interviews",[15],{"type":16,"name":17,"description":17,"armGroupLabels":18,"otherNames":10},"BEHAVIORAL","Interviews",[9],[20],{"name":21,"affiliation":22,"role":23},"Dori Beeler, PhD","Atrium Health Levine Cancer","PRINCIPAL_INVESTIGATOR",[25],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},"Megan Lattanze","CONTACT","(980) 442-4239","Megan.Lattanze@advocatehealth.org",[31,47],{"facility":22,"status":32,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Charlotte","North Carolina","28204","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-80.84313,35.22709,{"lat":42,"lon":41},[45,46],{"name":26,"role":27,"phone":28,"phoneExt":10,"email":29},{"name":21,"role":23,"phone":10,"phoneExt":10,"email":10},{"facility":48,"status":32,"city":49,"state":34,"zip":50,"country":36,"countryCode":37,"cosmosGeoPoint":51,"geoPoint":55,"contacts":56},"Wake Forest Baptist Comprehensive Cancer Center","Winston-Salem","27157",{"type":39,"coordinates":52},[53,54],-80.24422,36.09986,{"lat":54,"lon":53},[57,60],{"name":21,"role":27,"phone":58,"phoneExt":10,"email":59},"980-442-7883","Dori.Beeler@advocatehealth.org",{"name":61,"role":23,"phone":10,"phoneExt":10,"email":10},"Dori Beeler",{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[65],{"name":66,"class":6},"Atrium Health Levine Cancer Institute","100559712","cancer-related-fatigue-during-maintenance-immunotherapy-for-non-small-cell-lung-cancer-nsclc-a-qualitative-study-100559712",false,"NCT06567704","Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study","Inclusion Criteria:\n\n* ≥ 18 years of age at the time of consent.\n* Must be able to speak, read, and understand English.\n* Participants diagnosed with NSCLC, and:\n\n  * have advanced\u002Fmetastatic disease who are currently receiving immunotherapy monotherapy, or\n  * have locally advanced disease who are currently receiving immunotherapy monotherapy after completing thoracic radiation therapy, or\n  * who underwent resection and are currently receiving immunotherapy monotherapy after completing all other perioperative treatment\n* Immunotherapy planned to continue for at least three months after the time of study enrollment (to ensure participant remains on IO long enough to obtain study assessments)\n* Have completed at least two cycles of immunotherapy.\n* Self-reported cancer-related fatigued that impacts daily function.\n\nExclusion Criteria:\n\n* Participants who have received a dose of chemotherapy (including maintenance pemetrexed) within the past 3 months\n* Participants who have received radiation therapy within the past 3 months. Note: a short course of palliative radiation therapy within up to 20 Gy and up to 5 fractions is permissible.\n* Diagnosis of dementia.\n* Anemia Hgb \\\u003C10 g\u002FdL.\n* Sarcopenia which is being pharmacologically treated with a prescribed appetite stimulant (e.g., megestrol).\n* Untreated hypothyroidism.\n* Symptomatic heart failure.\n* Oxygen dependent lung disease.\n* Cognitively unable to complete interviews per investigator.","ALL","18 Years",{"count":76,"type":77},20,"ESTIMATED","OBSERVATIONAL","The purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (NSCLC), who are being treated with an immune checkpoint inhibitor.",[81],"Non-small Cell Lung Cancer",[83,84],"Cancer related fatigue","Immune checkpoint inhibitor","2026-08-05",{"date":87,"type":88},"2026-08-10","ACTUAL",{"date":90,"type":88},"2025-03-26",{"date":92,"type":77},"2027-07",{"name":5,"class":6},2]